{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-280141","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.651540+00:00","generated_at":"2026-05-16T20:31:54.242054+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioAtla Q3 net loss $15.8M; FDA aligns on Phase 3 Oz-V design; partnership on track by year-end","bullets":["Q3 2025 net loss $15.8M vs $10.6M in 2024 (which included $11M Context collaboration revenue); cash $8.3M at Sept 30.","FDA alignment achieved on Phase 3 Oz-V trial for 2L+ OPSCC; dual primary endpoints (ORR and OS) with potential accelerated approval.","Company in advanced stages to finalize a strategic transaction by year-end; Context milestone payment of $2M received.","BA3182 (CAB-EpCAM x CD3 TCE) Phase 1 dose escalation ongoing; readout expected in first half 2026.","R&D expenses decreased to $9.5M from $16.4M due to program prioritization and workforce reduction in March 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-280141","json":"https://secwatch.observer/filing/0001193125-25-280141.json","markdown":"https://secwatch.observer/filing/0001193125-25-280141.md","text":"https://secwatch.observer/filing/0001193125-25-280141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000119312525280141/0001193125-25-280141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000119312525280141/bcab-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:31:54.242054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}